Ectoparasite saliva proteins and apparatus to collect such proteins
AssigneeHeska Corporation
InventorsGlenn R. Frank, Shirley Wu Hunter, Lynda Wallenfels
Life of this patent
Estimating the term…
Loading patent…
AssigneeHeska Corporation
InventorsGlenn R. Frank, Shirley Wu Hunter, Lynda Wallenfels
Estimating the term…
The present invention is directed to a novel product and method for isolating ectoparasite saliva proteins, and a novel product and method for detecting and/or treating allergic dermatitis in an animal. The present invention includes a saliva protein collection apparatus capable of collecting ectoparasite saliva proteins substantially free of contaminating material. The present invention also relates to ectoparasite saliva proteins, nucleic acid molecules having sequences that encode such proteins, and antibodies raised against such proteins. The present invention also includes methods to obtain such proteins and to use such proteins to identify animals susceptible to or having allergic dermatitis. The present invention also includes therapeutic compositions comprising such proteins and their use to treat animals susceptible to or having allergic dermatitis.
A formulation comprising at least one isolated ectoparasite saliva protein, wherein said ectoparasite saliva protein comprises at least a portion of an amino acid sequence, wherein said portion is encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions with a nucleic acid molecule that encodes a flea saliva protein present in a flea saliva extract selected from the group consisting of FS-1, FS-2 and FS-3 flea saliva extracts, wherein said formulation is substantially free of non-saliva ectoparasite proteins.
A formulation comprising at least one isolated ectoparasite saliva protein, wherein said ectoparasite saliva protein comprises at least a portion of an amino acid sequence, wherein said portion is encoded by a nucleic acid molecule capable of hybridizing under stringent conditions with a nucleic acid molecule that encodes a flea saliva protein represented as a protein peak in FIG. 2, wherein said formulation is substantially free of non-saliva ectoparasite proteins.
A formulation comprising at least one isolated ectoparasite saliva product substantially free of contaminating material, said formulation being produced by a process comprising:
A therapeutic composition for treating allergic dermatitis comprising a formulation comprising at least one isolated ectoparasite saliva protein, wherein said ectoparasite saliva protein comprises at least a portion of an amino acid sequence, wherein said portion is encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions with a nucleic acid molecule that encodes a flea saliva protein present in a flea saliva extract selected from the group consisting of FS-1, FS-2 and FS-3 flea saliva extracts, wherein said formulation is substantially free of non-saliva ectoparasite proteins.
A formulation comprising at least one isolated ectoparasite saliva protein, wherein said ectoparasite saliva protein comprises at least a portion of an amino acid sequence, wherein said portion is encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions with a nucleic acid molecule that encodes a flea saliva protein present in a flea saliva extract selected from the group consisting of FS-1, FS-2 and FS-3 flea saliva extracts, wherein said formulation is produced by a process selected from the group consisting of:
Dependencies are inferred from the claim text.